Tagged Articles

Actos 310 articles

Takeda to pay $2 million in latest Actos bladder cancer trial

A Philadelphia jury deliberated more than five hours before ordering Takeda Pharmaceutical Co., was ordered to pay more than $2 million to a woman who claimed the company’s type 2 diabetes drug Actos caused her to develop bladder cancer. The verdict is the latest of thousands involving Actos bladder cancer claims to go to trial. Plaintiff Frances Wisniewski argued that Japan-based Takeda knew of the bladder cancer risks associated with Actos but failed to adequately warn doctors or patients of the risk. Wisniewski is the seventh Actos user to go to trial. A previous case resulted in a $9 billion ... Read More

Plaintiff claims Actos bladder cancer warnings were not strong enough to convey risks

Takeda Pharmaceutical Co., attempted to convince a Philadelphia jury that it adequately warned of bladder cancer risks on the label of its type 2 diabetes drug Actos by presenting testimony from a former senior official with the Food and Drug Administration (FDA) David Feigal Jr., an expert witness for the drug company, said that Takeda had funded several studies to gauge the cancer risks with its once-blockbuster drug and had included that information on the drug’s insert. However, plaintiff Frances Wisniewski claims differently. She took Actos for seven years and developed tumors in her bladder. Her lawsuit alleges that Takeda ... Read More

Newly approved type 2 diabetes drug carries black box warning for thyroid cancer risk

The Food and Drug Administration (FDA) has approved Eli Lilly and Co.’s new Type 2 diabetes treatment Trulicity, but the approval comes with a black box warning about an increased risk of thyroid cancer. Trulicity is an injectable drug in a family of type 2 diabetes medications known as glucagon-like peptide-1, or GLP-1, receptors. These drugs are in class of medications known as incretin mimetics that help control blood sugar levels in patients who do not produce enough insulin. Trulicity can be used as a single treatment or in combination with other commonly prescribed diabetes drugs including metformin, Actos and ... Read More

Controlling blood sugar does not prevent heart attacks, strokes, death

People with type 2 diabetes can protect themselves against heart attacks, strokes and death by intensively lowering their blood pressure, but intensive blood sugar control did not produce the same benefits, according to new research published in the New England Journal of Medicine. The study involved nearly 8,500 participants who had completed a diabetes trial during which some patients had their blood pressure and blood sugar levels strictly controlled, and others received standard care. The diabetes trial had shown a clear benefit from blood pressure reduction and blood sugar lowering. However, the unanswered question was whether the benefits go away or ... Read More

Takeda faces damning testimony in Actos bladder cancer lawsuit

Upjohn Co. allegedly backed out of development of the type 2 diabetes drug Actos in 1993 because of safety concerns, according to court testimony. However, Takeda Pharmaceuticals, the drug’s maker, urged Upjohn to say that it was backing away from the project because it didn’t believe the drug would be effective in the treatment of diabetes, an expert witness for the plaintiffs said. Randall Tackett, a pharmacologist and toxicologist at the University of Georgia, testified on behalf of plaintiff Frances Wisniewski, who is suing Takeda over claims that the Japanese drug maker’s diabetes medication Actos caused her to develop bladder cancer, ... Read More

Artificial sweeteners may increase the risk of type 2 diabetes

Using artificial sweeteners may disrupt the way the body handles sugar, increasing the risk of diabetes for some people, according to a new study published in the journal Nature. The research, conducted primarily on laboratory animals, suggests that artificial sweeteners, such as Splenda, Equal and NutraSweet, can change the bacteria that normally resides in the gut. When this happens, it disrupts how the body handles sugar in the diet, which can lead to increased blood sugar levels, a condition called glucose intolerance, which is a precursor to type 2 diabetes. Researchers say that it is too early to caution people ... Read More

New diabetes research center opens at University of Iowa

The University of Iowa has opened a new Diabetes Research Center dedicated to finding treatments and cures for diabetes. “The goal ultimately is to really help the University of Iowa become a major hub for cutting-edge diabetes research that will really capture the attention of the world,” said Dr. E. Dale Abel, the center’s director. Researchers at the university have been working various pilot projects in the past three years, including research on glucose production, natural treatments for diabetic nerve disease, and experimental drugs such as FGF21, which has been shown to have beneficial effects on lipid, body weight and ... Read More

FDA grants tentative approval to new insulin treatment for diabetes

Tentative approval has been granted to Eli Lilly & Co. for its new insulin drug to control blood sugar levels in diabetic patients. Basaglar is indicated for adults with type 2 diabetes and in combination with mealtime insulin for adults and children with type 1 diabetes. Lilly partnered with Boehringer Ingelheim in the drug’s development. Tentative approval means that Basaglar meets all the regulatory requirements needed for full approval but due to patent infringement claims filed by drugmaker Sanofi, final approval cannot be granted until mid-2016, or unless a court rules in favor of Lilly. An estimated 29 million Americans ... Read More

Judge refuses to throw out $9 billion judgment against Actos makers

A Louisiana federal judge refused to throw out a $9 billion judgment against Takeda Pharmaceuticals and Eli Lilly & Co., alleging the companies hid bladder cancer risks with its blockbuster type 2 diabetes drug Actos. The April verdict was in favor of plaintiffs Terrence and Susan Allen, who claimed the drug companies withheld from doctors and patients information about bladder cancer risks associated with Actos. It was the first U.S. trial of its kind, setting the stage for thousands of other similar lawsuits against Takeda and Eli Lilly involving Actos and bladder cancer. Japan-based Takeda was ordered to pay $6 billion ... Read More

Teens whose mothers had gestational diabetes are at greater risk of type 2 diabetes

Obese teenagers whose mothers had gestational diabetes while pregnant with them are at greater risk of developing Type 2 diabetes, a new study shows. The study, conducted by researchers with the Hebrew University in Jerusalem, found that among obese children who had a normal initial glucose tolerance, those whose mothers had gestational diabetes were six times more likely to develop impaired glucose tolerance or type 2 diabetes by the time they reached age 15. This is concerning particularly because the number of women with gestational diabetes is increasing, which researchers warn could indicate more children will develop diabetes in the ... Read More